Yamaja B Setty

Relationship of Omega-3 fatty acids DHA and EPA with the inflammatory biomarker hs-CRP in children with sickle cell anemia; Prostaglandins Leukotrienes and Essential Fatty Acids; (2019).

Quantitative sensory testing in children with sickle cell disease: additional insights and future possibilities; British Journal of Haematology; (2019).

Tissue factor-positive monocytes in children with sickle cell disease: Correlation with biomarkers of haemolysis; British Journal of Haematology; (2012).

Tapered oral dexamethasone for the acute chest syndrome of sickle cell disease; British Journal of Haematology; (2011).

Increased levels of the inflammatory biomarker C-reactive protein at baseline are associated with childhood sickle cell vasocclusive crises; British Journal of Haematology; (2010).

Phosphatidylserine-positive erythrocytes bind to immobilized and soluble thrombospondin-1 via its heparin-binding domain; Translational Research; (2008).

Heme induces endothelial tissue factor expression: Potential role in hemostatic activation in patients with hemolytic anemia; Journal of Thrombosis and Haemostasis; (2008).

Vaso-occlusion in children with sickle cell disease: Clinical characteristics and biologic correlates; Journal of Pediatric Hematology/Oncology; (2004).

Hypoxaemia in sickle cell disease: Biomarker modulation and relevance to pathophysiology; Lancet; (2003).

Eicosanoids in sickle cell disease: Potential relevance of neutrophil leukotriene B₄ to disease pathophysiology; Journal of Laboratory and Clinical Medicine; (2002).

Acute chest syndrome of sickle cell disease: New light on an old problem; Current Opinion in Hematology; (2001).

Hemostatic alterations in sickle cell disease: Relationships to disease pathophysiology; Pediatric Pathology and Molecular Medicine; (2001).

Fetal hemoglobin in sickle cell disease: Relationship to erythrocyte phosphatidylserine exposure and coagulation activation; Blood; (2000).

Measurement of hemoglobin saturation by oxygen in children and adolescents with sickle cell disease; Pediatric Pulmonology; (1999).

Sickle cell acute chest syndrome: Pathogenesis and rationale for treatment; Blood; (1999).

Eicosanoids in sickle cell disease: Potential relevance of 12(S)-hydroxy-5,8,10,14-eicosatetraenoic acid to the pathophysiology of vaso-occlusion; Journal of Laboratory and Clinical Medicine; (1998).

Sickle red blood cells stimulate endothelial cell production of eicosanoids and diacylglycerol; Journal of Laboratory and Clinical Medicine; (1996).

Impaired mobilization of intracellular calcium in neonatal platelets; Pediatric Research; (1996).

Vascular cell adhesion molecule-1 is involved in mediating hypoxia- induced sickle red blood cell adherence to endothelium: Potential role in sickle cell disease; Blood; (1996).

Arachidonic acid metabolites are involved in mediating red blood cell adherence to endothelium; Journal of Laboratory and Clinical Medicine; (1995).

Sickle cell vaso-occlusive crisis is associated with abnormalities in the ratio of vasoconstrictor to vasodilator prostanoids; Pediatric Research; (1995).

Intravenous morphine pharmacokinetics in pediatric patients with sickle cell disease; The Journal of Pediatrics; (1995).

15-Hydroxyeicosatetraenoic acid-mediated potentiation of thrombin-induced platelet functions occurs via enhanced production of phosphoinositide-derived second messengers - sn-1,2-Diacylglycerol and inositol-1,4,5-trisphosphate; Blood; (1992).

Identification of prostaglandins and hydroxyeicosatetraenoic acids in kitten retina: Comparison with other species; Experimental Eye Research; (1991).

Effects of changes in oxygen tension on lipoxygenase metabolites. Serum 15-HETE is increasd in kittens exposed to hyperoxia; Biology of the Neonate; (1990).

15-hydroxyeicosatetraenoic acid stimulates migration of human retinal microvessel endothelium in vitro and neovascularization in vivo; Prostaglandins; (1990).

Changes in oxygen tension and effects on cyclooxygenase metabolites: III. Decrease of retinal prostacyclin in kittens exposed to hyperoxia; Pediatrics; (1988).

13-Hydroxyoctadeca-9,11-dienoic acid (13-HODE) inhibits thromboxane A₂ synthesis, and stimulates 12-HETE production in human platelets; Biochemical and Biophysical Research Communications; (1987).

The platelet cyclooxygenase metabolite 12-L-hydroxy-5, 8, 10- hepta- decatrienoic acid (HHT) may modulate primary hemostasis by stimulating prostacyclin production; Prostaglandins; (1987).

13-Hydroxyoctadecadienoic acid (13-HODE) stimulates prostacyclin production by endothelial cells; Biochemical and Biophysical Research Communications; (1987).

The mitogenic effect of 15- and 12-hydroxyeicosatetraenoic acid on endothelial cells may be mediated via diacylglycerol kinase inhibition; Journal of Biological Chemistry; (1987).

Time-dependent inhibition of platelet cyclo-oxygenase by indomethacin is slowly reversible; Prostaglandins; (1986).

15-Hydroxy-5,8,11,13-eicosatetraenoic acid inhibits human vascular cyclooxygenase. Potential role in diabetic vascular disease; Journal of Clinical Investigation; (1986).

Effects of changes in oxygen tension on vascular and platelet hydroxyacid metabolites. II. Hypoxia increases 15-hydroxyeicosatetraenoic acid, a proangiogenic metabolite; Pediatrics; (1985).

Formation of 11-hydroxyeicosatetraenoic acid and 15-hydroxyeicosatetraenoic acid in human umbilical arteries is catalyzed by cyclooxygenase; Biochimica et Biophysica Acta (BBA)/Lipids and Lipid Metabolism; (1985).

15-hydroxyeicosatetraenoic acid (15-HETE) inhibits cyclooxygenase activity in endothelial cells; Federation Proceedings; (1985).

Formation of 11-hete and 15-hete in human umbilical arteries is catalyzed by cyclooxygenase; Federation Proceedings; (1984).